LSB_OUT_1 [2025-04-03 09:41:40 -0400] 3035 Bytes | 826 tokens | Cum: 826 tkns (10.32% of 8k)
==========================================================================

We are in the 'Lightning Round' baby! It's 9:41:39 AM on Thu Apr 03, 2025 -0400, and I'm firing up the spotlight on LakeShore Biopharma (LSB), moving from 2.29 to 2.69. Is this a can’t-miss rocket or a one-hit wonder? Let’s dissect the numbers!

--- COMPANY PROFILE ---
Company: LakeShore Biopharma (LSB)
IPO: 2023-03-17 (2 Years Ago)
Market Cap: $45,793,802
Shares Outstanding: 19,080,000
Exchange: XNAS
Description: LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.

Here's the first list of news for LakeShore Biopharma:

C1 - Dec-19-24 09:05AM - LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance
C2 - Dec-12-24 07:57PM - LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China
C3 - Nov-07-24 08:00AM - LakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regulatory Authority of Pakistan
C4 - Oct-29-24 08:30AM - LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
C5 - Oct-26-24 09:00AM - LakeShore Biopharma Advances with Rabies Vaccine Trial
C6 - Oct-25-24 08:30AM - LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine
C7 - Oct-08-24 08:30AM - LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance
C8 - Sep-27-24 07:00AM - LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation

Prior AI Reports for LSB:
1. 2025-03-21 – Score: 50 – Target: 3.6600 – Highs: 2.8000 / 2.7800 / 2.75
lakeshore-biopharma-shows-resilience-amid-challenging-financial-times

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on LakeShore Biopharma (LSB)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

LSB_OUT_3 [2025-04-03 09:41:41 -0400] 1099 Bytes | 301 tokens | Cum: 1129 tkns (14.11% of 8k)
==========================================================================

Showing C1 (chunk 1 of 16): C1:
**LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance**
Date: Dec-19-24 09:05AM
Source: (PR Newswire)
URL: https://www.prnewswire.com/news-releases/lakeshore-biopharma-reports-unaudited-financial-results-for-the-first-half-of-fiscal-year-2025-and-updates-full-year-guidance-302336215.html

BEIJING,Dec. 19, 2024/PRNewswire/ -- LakeShore Biopharma Co., Ltd. (Nasdaq:LSB) ("LakeShore" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced its financial results for the first six months endedSeptember 30, 2024("FY2025H1").

"We are thrilled with the outstanding financial performance achieved in the first half of FY2025 under the leadership of our n

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

LSB_OUT_5 [2025-04-03 09:41:42 -0400] 589 Bytes | 172 tokens | Cum: 1303 tkns (16.29% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-21T13:00:00Z - Pre-market Movers: ALUR, IBO, PNBK, RNAZ, DSS....
A2 - 2025-03-21T12:10:22Z - 12 Health Care Stocks Moving In Friday's Pre-Market Session - Benitec Biopharma (NASDAQ:BNTC), Artiv...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

LSB_OUT_7 [2025-04-03 09:41:51 -0400] 1098 Bytes | 410 tokens | Cum: 1715 tkns (21.44% of 8k)
==========================================================================

Showing A1 (chunk 1 of 2): A1:
**Pre-market Movers: ALUR, IBO, PNBK, RNAZ, DSS.**Date: 2025-03-21Source: {'uri': 'finanznachrichten.de', 'dataType': 'news', 'title': 'FinanzNachrichten.de'}URL: https://www.finanznachrichten.de/nachrichten-2025-03/64892858-pre-market-movers-alur-ibo-pnbk-rnaz-dss-020.htmBEIJING (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.10 A.M. ET).

In the Green

Allurion Technologies Inc. (ALUR) is up over 64% at $3.75. Impact BioMedical Inc. (IBO) is up over 49% at $3.11. Patriot National Bancorp, Inc. (PNBK) is up over 31% at $1.39. TransCode Therapeutics, Inc. (RNAZ) is up over 31% at $1.01. DSS, Inc. (DSS) is up over 21% at $1.12. Regencell Bioscience Holdings Limited (RGC) is up over 20% at $54.00. LakeShore Biopharma Co., Ltd (LSB) is up over 10% at $2.32. Sera Prognostics, Inc. (SERA) is up over 9% at $4.29. TEN Holdings, Inc.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

LSB_OUT_9 [2025-04-03 09:41:52 -0400] 399 Bytes | 105 tokens | Cum: 2019 tkns (25.24% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-12-13T00:57:00Z - LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

LSB_OUT_11 [2025-04-03 09:41:57 -0400] 884 Bytes | 226 tokens | Cum: 2247 tkns (28.09% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/12/13/2996586/0/en/LakeShore-Biopharma-Provides-Update-on-Ongoing-Criminal-Investigation-Involving-Former-Chairman-in-China.htmlLakeShore Biopharma, a global biopharmaceutical company, announced that the Shenyang Municipal Public Security Bureau in China has initiated criminal investigations into actions taken by the company's former chairman, Yi Zhang, who is accused of misappropriating corporate assets and mismanaging the company, resulting in significant financial losses.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

LSB_OUT_13 [2025-04-03 09:41:58 -0400] 238 Bytes | 59 tokens | Cum: 2405 tkns (30.06% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

LSB_OUT_15 [2025-04-03 09:42:11 -0400] 3285 Bytes | 821 tokens | Cum: 3229 tkns (40.36% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+------------------------+
| Volume: 0 | Perf Month: 12.26% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+--------------------+-----------------------+------------------------+------------------------+
| Avg Volume: 11.64K | Perf Quarter: -28.44% | Short Float: 0.22% | ROE: - |
+--------------------+-----------------------+------------------------+------------------------+
| Rel Volume: 0.00 | Index: - | Short Ratio: 0.62 | ROI: - |
+--------------------+-----------------------+------------------------+------------------------+
| RSI (14): 47.89 | Market Cap: 43.69M | Short Interest: 0.01M | Sales Surprise: 15.02% |
+--------------------+-----------------------+------------------------+------------------------+
| ATR (14): 0.22 | Shs Outstand: 190.23M | Beta: 0.57 | EPS Surprise: -44.91% |
+--------------------+-----------------------+------------------------+------------------------+
| SMA20: 1.08% | Shs Float: 3.30M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+------------------------+------------------------+
| SMA50: -2.46% | Inst Own: 0.69% | Sales past 5Y: - | Earnings: - |
+--------------------+-----------------------+------------------------+------------------------+
| SMA200: -38.88% | Insider Own: 82.69% | Employees: 758 | |
+--------------------+-----------------------+------------------------+------------------------+
| Perf Week: -14.87% | Insider Trans: 0.00% | Debt/Eq: 0.73 | |
+--------------------+-----------------------+------------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 2.29
Average Volume: 14918.45
30-Day High: 2.7699
30-Day Low: 1.85
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

LSB_OUT_17 [2025-04-03 09:42:14 -0400] 676 Bytes | 167 tokens | Cum: 3671 tkns (45.89% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

LSB_IN_19 [2025-04-03 09:42:14 -0400] 126 Bytes | 29 tokens | Cum: 3728 tkns (46.60% of 8k)
==========================================================================

====================================
[2025-04-03 09:42:14] # Analysis Completed
Elapsed Time: 35.48 seconds